Distribution of individuals in every genotype score group and cumulative effects of the risk alleles from the 36 SNPs for glucose levels.

<p>The bar plots show the average and standard error of glucose in mmol/L for each genotype score group distribution of the genetic risk score.</p

Associations of the unweighted Genetic Risk Score (GRS) and the weighted Genetic Risk Score (wGRS) with glucose levels for the meta-analysis of the GOMAP and THISEAS studies ^a.

<p>Associations of the unweighted Genetic Risk Score (GRS) and the weighted Genetic Risk Score (wGRS) with glucose levels for the meta-analysis of the GOMAP and THISEAS studies <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0186669#t001fn001" target="_blank">^a</a>.</p

Associations of the unweighted Genetic Risk Score (GRS) and the weighted Genetic Risk Score (wGRS) with glucose levels for the meta-analysis of the GOMAP and THISEAS studies ^b.

<p>Associations of the unweighted Genetic Risk Score (GRS) and the weighted Genetic Risk Score (wGRS) with glucose levels for the meta-analysis of the GOMAP and THISEAS studies <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0186669#t002fn001" target="_blank">^b</a>.</p

Additional file 1: of Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study

Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study. Description of survey flow. Diagnostic assessment of T2D and psychiatric disease. Physical assessments. Table S1. T2D occurrence based on simple logistic regression modelling among patients with SCZ. Figure S1. Manhattan plot of association results from a GWAS on T2D in individuals receiving a combination of three or more psychotropic drugs, including one FGA and one SGA. For each of the 9,565,382 analysed variants the –log10 of the p-value is plotted against its chromosomal position. Blue and red lines indicate suggestive (p < 5*10− 6) and genome-wide (p < 5*10− 8) significance. Figure S2. Quantile-quantile plot of association results from a GWAS on T2D in individuals receiving a combination of three or more psychotropic drugs, including one FGA and one SGA. For each SNP the –log10 of the p-value is plotted against its expected value under the null distribution. (DOCX 219 kb

Estimated change in service users’ autonomy and experiences of care given an increase of 10% in each QuIRC domain.

<p>QuIRC  =  Quality Indicator for Rehabilitative Care.</p><p>RCS  =  Resident Choice Scale.</p><p>YTC  =  Your Treatment and Care.</p

Percentage of unit-to-unit variance in service user outcomes explained by QuIRC domain scores using three models.

<p>QuIRC  =  Quality Indicator for Rehabilitative Care.</p><p>Model A: QuIRC domain score entered as the only independent variable.</p><p>Model B: unit type (hospital or community) added to Model A.</p><p>Model C: service user characteristics added to Model B (age, GAF and psychosis or not).</p><p>Differences in % variance for each model also shown: B–A, C–B.</p